低分子肝素联合前列地尔治疗高脂血症性SAP患者的临床疗效

doi:10.3969/j.issn.1671-7171.2024.03.019

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1148 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical efficacy of low molecular weight heparin combined with alprostadil in the treatment of patients with hyperlipidemic severe acute pancreatitis(SAP). 【Methods】A total of 92 patients with hyperlipidemic SAP admitted to our hospital from July 2020 to July 2022 were selected and randomly divided into an observation group and a control group using a random number table method, with 46 cases in each group. The control group was treated with alprostadil on the basis of conventional treatment, while the observation group was treated with low molecular weight heparin on the basis of the control group's treatment. The conditions of recovery, Ranson score, Sequential Organ Failure Assessment(SOFA) score, hemorheological indexes [D-dimer(D-D), plasma viscosity, fibrinogen(FIB), platelet aggregation rate], blood lipid levels [low density lipoprotein cholesterol(LDL-C), triglyceride(TG), high density lipoprotein cholesterol(HDL-C)], inflammatory factors [white blood cell count(WBC), tumor necrosis factor-α(TNF-α), procalcitonin(PCT)], and prognosis were compared between the two groups. 【Results】After treatment, the mechanical ventilation time, abdominal pain subsidence time, ICU hospitalization time, and intestinal function recovery time in the observation group were shorter than those in the control group(P<0.05); the Ranson score and SOFA score in both groups were lower than those before treatment, and the observation group was lower than the control group, with significant differences(P<0.05); D-D, plasma viscosity, FIB, platelet aggregation rate in the observation group were lower than those before treatment, and those in the observation group were lower than those in the control group, with significant differences(P<0.05); LDL-C, TG in both groups were lower than those before treatment, HDL-C was higher than those before treatment, LDL-C, TG in the observation group were lower than those in the control group, HDL-C was higher than those in the control group, with significant differences(P<0.05); PCT, TNF-α, WBC in both groups were lower than those before treatment, and those in the observation group were lower than those in the control group(P<0.05). The total incidence of complications and recurrence rate in the observation group were lower than those in the control group, with significant differences(P<0.05). 【Conclusion】 Low molecular weight heparin combined with alprostadil has better clinical efficacy in the treatment of hyperlipidemic SAP, which can promote patient recovery, improve microcirculation, reduce lipids and inflammation, and help improve patient prognosis.

Key words： Hyperlipidemias/CO Pancreatitis/CO Heparin, Low-Molecular-Weight/PD Alprostadil/PD Treatment Outcome

Received: 18 June 2023

PACS:

R576.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAN Xiaohuan
	LI Meixia
	WU Nana

Cite this article:

HAN Xiaohuan,LI Meixia,WU Nana. Clinical Efficacy of Low Molecular Weight Heparin Combined with Alprostadil in the Treatment of Patients with Hyperlipidemic SAP[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(3): 389-392.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.03.019 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I3/389

[1] 张娟,章润叶,杨淑洁.中心静脉-动脉血二氧化碳分压差/动脉-中心静脉血氧含量差比值与重症急性胰腺炎患者器官衰竭的相关研究[J].现代消化及介入诊疗,2022,27(5):616-619.
[2] 黄文炼,刘鸿雁,祝瑞,等.重症急性胰腺炎并发急性呼吸窘迫综合征发病特点、死亡因素分析及风险评估模型的建立[J].安徽医药,2022,26(6):1187-1192.
[3] 周明春,王震.柴芍承气汤联合低相对分子质量肝素钙治疗高脂血症性胰腺炎患者临床疗效及对炎症介质、血脂水平与凝血功能的影响[J].血栓与止血学,2021,27(2):224-225.
[4] 陈瑶,向正国,郑扬.前列地尔联合双歧杆菌对急性胰腺炎患者的疗效及对肠屏障功能和闭合蛋白水平的影响[J].临床急诊杂志,2022,23(1):15-18.
[5] 尹小勇,董科,杨正东,等.乳酸、血浆D-二聚体、纤维蛋白原联合检测对高脂血症性胰腺炎严重程度及预后评价[J].西部医学,2021,33(7):1001-1004.
[6] 中华医学会外科学分会胰腺外科学组.中国急性胰腺炎诊治指南(2021)[J].中华消化外科杂志,2021,20(7):730-739.
[7] 李梦蝶,许明,史新格,等.早期血液灌流联合连续性静脉-静脉血液滤过治疗高脂血症性重症急性胰腺炎的临床效果观察[J].中国中西医结合急救杂志,2021,28(6):662-667.
[8] 汤淼.乌司他丁联合奥曲肽对高脂血症性急性胰腺炎患者炎性介质及血液微循环状态的影响[J].当代医学,2021,27(30):59-62.
[9] 吴林,孔晓霞,郑桂贞,等.早期CRRT联合前列地尔治疗高脂血症性急性重症胰腺炎[J].西部医学,2022,34(2):270-275.
[10] 叶丹,柯丽,张川,等.奥曲肽联合前列地尔治疗高脂血症性急性胰腺炎疗效及对患者胃肠功能恢复血淀粉酶阴转率的影响[J].河北医学,2019,25(12):1975-1978.
[11] 张艳,张绣姜,孟哲,等.血清TG水平和BISAP评分对重症急性胰腺炎患者感染性胰腺坏死的预测价值[J].山东医药,2022,62(1):52-55.
[12] 张龙,尤宁.低相对分子质量肝素辅助治疗高脂血症性重症急性胰腺炎的效果及对凝血状态的影响[J].血栓与止血学,2022,28(3):614-615.
[13] 蔡华忠,李利毛,周峰,等.基于APACHE Ⅱ评分探讨血液灌流联合低分子肝素治疗高脂血症性急性胰腺炎的临床疗效及对机体炎症反应的影响[J].临床急诊杂志,2021,22(5):305-308.
[14] 赵凯,章阳.血清淀粉样蛋白A、CRP和PCT水平预测高脂血症性急性胰腺炎严重程度及预后的临床价值[J].标记免疫分析与临床,2021,28(2):268-272.
[15] 丁光伟,王全智,高春耕,等.低分子肝素联合胰岛素对高脂血症性胰腺炎的疗效及对血清炎症介质与凝血指标的影响[J].广东医学,2021,42(3):347-351.